Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: Pilot study

Therapeutic Advances in Psychopharmacology

Volumn 4, Issue 3, 2014, Pages 110-116

  Chaudhry, Imran B ^a   Husain, Nusrat ^a   Drake, Richard ^a   Dunn, Graham ^a   Husain, M Omair ^b   Kazmi, Ajmal ^c   Hamirani, Munir M ^d   Rahman, Raza ^e   Stirling, John ^f   Deakin, William ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b City Mental Health NHS Trust   (United Kingdom)

^c Pakistan Institute of Learning and Living   (Pakistan)

^d ABBASI SHAHEED HOSPITAL   (Pakistan)

^e DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^f NONE

Author keywords

anti inflammatory; ondansetron; Psychosis; schizophrenia; simvastatin

Indexed keywords

EID: 84997941958     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125313511487     Document Type: Article

References (23)

1. Akhondzadeh S. Mohammadi N. Noroozian M. Karamghadiri N. Ghoreishi A. Jamshidi A.H. et al. (2009) Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res 107: 206–212.
2. Akhondzadeh S. Rezaei F. Larijani B. Nejatisafa A. Kashani L. Abbasi S. (2006) Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr Res 84: 405–410.
3. British National Formulary (BNF) (2012). British Medical Association, Royal Pharmaceutical Society of Great Britain, Edited by Joint Formulary Committee.
4. Castilla G. Del Carmen Fernandez M. Lopez Chozas J. Jimenez H. (2008) Statins in stroke prevention: what an internist should know. Eur J Intern Med 19: 8–14.
5. Dickerson F. Stallings C. Origoni A. Boronow J. Yolken R. (2007) C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93: 261-265.
6. Fan X. Pristach C. Liu E. Freudenreich O. Henderson D. Goff D. (2007) Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 149: 267-271.
7. Freeman D. Norrie J. Sattar N., Neely, R.D., Cobbe, S.M., Ford I. et al. (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103: 357–362.
8. Guy W. (1976) ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW publication number ADM 76-338). Rockville, MD: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, pp. 534–537.
9. Kay S. Fisbein A. Opler L. (1997) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.
10. Laan W. Grobee D. Selten J. Heijnen C. Kahn R. Burger H. (2010) Adjuvant aspirin reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71: 520-527.
11. Lancaster G. Dodd S. Williamson P. (2004) Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 10: 307–312.
12. Levkovitz Y. Arnest G. Mendlovic S., Treves, I. and Fennig, S. et al. (2005) The effect of ondansetron on memory in schizophrenic patients. Brain Res Bull 65: 291–295.
13. Marty M. Pouillart P. Scholl S. Droz J. Azab M. Brion N. et al. (1990) Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322: 816-821.
14. Müller N. Schwarz M. (2008) COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 14: 1452-1465.
15. Nassief A. Marsh J. (2008) Statin therapy for stroke prevention. Stroke 39: 1042–1048.
16. Plenge J. Hernandez T. Weil K. Poirier P. Grunwald G. Marcovina S. et al. (2002) Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106: 1447-1452.
17. Ridker P. Rifai N. Pfeffer M. Sacks F.M. Moye L.A. Goldman S. et al. (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98: 839–844.
18. Sirota P. Mosheva T. Shabtay H. Giladi N. Korczyn A. (2000) Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiatry 157: 2.
19. Sirota P. Mosheva T. Shabtai H. Korczyn A. (2001) Treating tardive dyskinesia with ondansetron. J Clin Psychopharmacol 21: 355-356.
20. van der Most P. Dolga A. Nijholt I. Luiten P. Eisel U. (2009) Statins: mechanisms of neuroprotection. Prog Neurobiol 88: 64–75.
21. White L. Harvey P. Opler L. Lindenmayer J. (1997) Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: a multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology 30: 263–274.
22. Zhang Z. Kang W. Li Q. Wang X.Y. Yao S.M. Ma A.Q. (2006) Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res 88: 102–110.
23. Zoldan J. Friedberg G. Livneh M. Melamed E. (1995) Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5HT3 receptor antagonist. Neurology 45: 1305–1308.